Results 131 to 140 of about 43,174 (164)

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies [PDF]

Journal of Thrombosis and Haemostasis, 2017
Essentials An international collaboration provides a consensus for clinical definitions. This concerns thrombotic microangiopathies and thrombotic thrombocytopenic purpura (TTP).
Flora Peyvandi, Marie Scully, Bernhard Lämmle   +2 more
exaly   +6 more sources

A rare case report of gemcitabine-induced thrombotic microangiopathies [PDF]

SAGE Open Medical Case Reports, 2021
Mohammed Madkhali
exaly   +2 more sources

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies

Blood, 2012
Thrombotic microangiopathies (TMAs) are a group of life-threatening disorders characterized by thrombocytopenia, fragmentation of erythrocytes, and ischemic organ damage. Genetic disorders, autoimmune disease, and cancer are risk factors for TMAs, but an
Tobias A Fuchs, Johanna A Kremer Hovinga, Denisa D Wagner   +2 more
exaly   +2 more sources

Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina [PDF]

EJHaem, 2021
Celia Dos Santos, Analia Sanchez-Luceros, Juvenal Paiva   +2 more
exaly   +2 more sources

Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies [PDF]

Journal of Thrombosis and Haemostasis, 2015
BACKGROUND Acute thrombotic microangiopathies (TMAs) are characterized by excessive microvascular thrombosis and are associated with markers of neutrophil extracellular traps (NETs) in plasma.
Bernhard Lämmle, S Peine, J A Kremer Hovinga   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Thrombotic Microangiopathy in the Cancer Patient

Acta Haematologica, 2001
Thrombotic microangiopathy, manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome, is a common complication in cancer patients. It shares the pathogenic microvascular occlusive lesion and many clinical manifestations as the classical TTP, but the spectrum of complications varies widely.
H C, Kwaan, L I, Gordon
openaire   +2 more sources

Gemcitabine‐induced thrombotic microangiopathy

Internal Medicine Journal, 2013
AbstractThrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end‐organ damage. It is commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated.
Richmond, J., Gilbar, P., Abro, E.
openaire   +5 more sources

[Thrombotic microangiopathy].

Der Internist, 2013
Thrombotic microangiopathy should be suspected every time the combination of microangiopathic hemolytic anemia without a coexisting cause, thrombocytopenia as well as renal and/or neurologic abnormalities occurs. The general term thrombotic microangiopathy includes different subtypes of the disease leading to abnormalities in multiple organ systems by ...
Ganser, A., Kielstein, J. T., Beutel, G.
openaire   +2 more sources

Thrombotic Microangiopathies and the Kidney

Advances in Kidney Disease and Health
Thrombotic microangiopathy (TMA) is a pathological lesion that occurs due to endothelial injury. It can be seen in a heterogenous group of disorders, typically characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ ischemia. TMA can also be renal limited with no systemic manifestations.
Anuja Java, Richard Burwick, Anthony Chang   +2 more
openaire   +2 more sources

Thrombotic microangiopathies

Critical Reviews in Oncology/Hematology, 1991
P, Ruggenenti, G, Remuzzi
openaire   +2 more sources